Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy-Reference-Cited by-同舟云学术

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy

Published:2023-05 Issue:3 Volume:24 Page:453-467
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Chatziioannou Eftychia^ORCID,Leiter Ulrike,Thomas Ioannis,Keim Ulrike,Seeber Olivia,Meiwes Andreas,Boessenecker Isabell,Gonzalez Stephanie Sanchez,Torres Francisco Merraz,Niessner Heike,Sinnberg Tobias,Forschner Andrea,Flatz Lukas,Amaral Teresa^ORCID

Funder

Universitätsklinikum Tübingen

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-023-00775-7.pdf

Reference53 articles.

1. McDermott D, Lebbé C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056–64.

2. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol. 2014;32(15 Suppl):LBA9000-LBA.

3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.